Many patients with atrial fibrillation (AFib) are not receiving any therapy to prevent stroke, and Geoffrey Barnes, MD, ...

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight ...

Eli Lilly announced that the FDA has expanded the US approval of baricitinib (Olumiant) to include patients aged 12 years and ...

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer. The FDA's action identifies the application as ...

Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day ...

Geoffrey Barnes, MD, on why a careful exam is the first line of detection and which 2 risk factors primary care clinicians can actually change. Many patients with atrial fibrillation (AFib) have no ...

, on why a careful exam is the first line of detection and which 2 risk factors primary care clinicians can actually change.

Drucker described a “start low and go slow” approach and says some patients respond while receiving relatively low doses. The FDA identifies nausea, diarrhea, vomiting, and constipation among common ...

Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.

The FDA has approved finerenone (Kerendia) for adults with chronic kidney disease (CKD) associated with type 1 diabetes (T1D), making it the first new FDA-approved treatment option for this population ...

The FDA has approved insulin efsitora alfa-gobe (Onswik, Eli Lilly), a once-weekly basal insulin, as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes. The approval, ...

FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years. The US Food and Drug Administration has approved Pfizer and BioNTech’s ...